GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Short-Term Debt

Biogen (MEX:BIIB) Short-Term Debt : MXN4,149 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Short-Term Debt?

Biogen's Short-Term Debt for the quarter that ended in Mar. 2024 was MXN4,149 Mil.

Biogen's quarterly Short-Term Debt declined from Sep. 2023 (MXN8,709 Mil) to Dec. 2023 (MXN2,546 Mil) but then increased from Dec. 2023 (MXN2,546 Mil) to Mar. 2024 (MXN4,149 Mil).

Biogen's annual Short-Term Debt declined from Dec. 2021 (MXN20,496 Mil) to Dec. 2022 (MXN0 Mil) but then increased from Dec. 2022 (MXN0 Mil) to Dec. 2023 (MXN2,546 Mil).


Biogen Short-Term Debt Historical Data

The historical data trend for Biogen's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Short-Term Debt Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28,210.79 - 20,495.54 - 2,546.14

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 8,709.45 2,546.14 4,149.06

Biogen Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Biogen Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Analyst Q&A Call Transcript

By GuruFocus Research 01-22-2024